Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CEQ 508

Drug Profile

CEQ 508

Alternative Names: CEQ508

Latest Information Update: 17 Oct 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Marina Biotech
  • Class Antineoplastics; RNA
  • Mechanism of Action Beta catenin inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Familial adenomatous polyposis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Familial adenomatous polyposis

Most Recent Events

  • 08 Sep 2017 Efficacy data from the phase I/II START-FAP trial in Familial adenomatous polyposis presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
  • 10 Jul 2017 The primary endpoint was met in the phase I/II START-FAP trial in Familial adenomatous polyposis
  • 13 Mar 2017 Marina Biotech completes phase I part of the START-FAP phase I/II trial in Familial adenomatous polyposis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top